| 000 | 01509 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250515130551.0 | ||
| 264 | 0 | _c20081020 | |
| 008 | 200810s 0 0 eng d | ||
| 022 | _a1533-001X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDesilva, Shani | |
| 245 | 0 | 0 |
_aSequential therapies for Crohn's disease: optimizing conventional and biologic strategies. _h[electronic resource] |
| 260 |
_bReviews in gastroenterological disorders _c2008 |
||
| 300 |
_a109-16 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAzathioprine _xadministration & dosage |
| 650 | 0 | 4 | _aBiological Therapy |
| 650 | 0 | 4 | _aCertolizumab Pegol |
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 |
_aGlucocorticoids _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xadministration & dosage |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aNatalizumab |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xadministration & dosage |
| 650 | 0 | 4 |
_aPrednisolone _xadministration & dosage |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aKaplan, Gil | |
| 700 | 1 | _aPanaccione, Remo | |
| 773 | 0 |
_tReviews in gastroenterological disorders _gvol. 8 _gno. 2 _gp. 109-16 |
|
| 999 |
_c18121635 _d18121635 |
||